Liraglutide

CHEMBL4084119 Phase 4 已批准 Protein
Half-Life
13 hours
Bioavailability
Protein Binding
Molecular Weight
3751.0 g/mol
LogP
-3.4
Phase
4

Receptor agonism at GLP-1 gives liraglutide its dual application in type 2 diabetes and in obesity. Mimicking the natural incretin, it enhances insulin secretion, suppresses appetite and slows gastric emptying, so glycaemic control and weight reduction arise from a single mechanism acting at pancreatic and central sites. Investigation has extended to cardiovascular and neuroprotective effects beyond those established indications. Its elimination half-life of about 13 hours is intermediate between the native hormone, degraded within minutes, and the weekly analogues developed subsequently. The agent is a protein of formula C172H265N43O51 and roughly 3751 g/mol, classified within the alimentary tract and metabolism group.

A GLP-1 receptor agonist used to treat type 2 diabetes and obesity, and studied for cardiovascular and neuroprotective benefits. It mimics the natural GLP-1 hormone to stimulate insulin secretion, suppress appetite, and slow stomach emptying.

分子量

3751.0000 g/mol

LogP

-3.40

TPSA

1510.00 Ų

Lipinski 五规则

不符合

治疗领域

药物分类

作用机制

GLP-1 receptor agonist enhancing insulin secretion.

Pharmacokinetics (PK)

Half-Life 13 hours

Pharmacodynamics (PD)

机制

GLP-1 receptor agonist enhancing insulin secretion.

二维结构

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)[C@@H](C)CC)C(=O)O

InChI

InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1

Molecular Formula

C172H265N43O51

HBD / HBA

54 / 55

可旋转键数

132

重原子数

266

No targets recorded

Target interaction data is not yet available for this drug.

No side effects recorded

Side effect data is not yet available for this drug.

常见问题

A GLP-1 receptor agonist used to treat type 2 diabetes and obesity, and studied for cardiovascular and neuroprotective benefits. It mimics the natural GLP-1 hormone to stimulate insulin secretion, suppress appetite, and slow stomach emptying.

GLP-1 receptor agonist enhancing insulin secretion.

Key pharmacokinetic parameters for Liraglutide: Half-life: 13 hours.

Yes, Liraglutide is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4084119. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 16134956. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

医疗免责声明

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.